Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 4
2008 4
2009 4
2010 3
2011 6
2012 2
2014 2
2016 1
2017 2
2018 4
2019 1
2020 5
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.
Mimori T, Shukuya T, Ko R, Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K. Mimori T, et al. Among authors: sugiyama t. Cancers (Basel). 2022 Jan 11;14(2):331. doi: 10.3390/cancers14020331. Cancers (Basel). 2022. PMID: 35053494 Free PMC article.
Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302.
Kasai T, Mori K, Sugiyama T, Koyama N, Nakamura Y, Ohyanagi F, Fukuda H, Hoshi E, Kobayashi K, Nakayama M. Kasai T, et al. Among authors: sugiyama t. Int J Clin Oncol. 2022 Dec;27(12):1841-1848. doi: 10.1007/s10147-022-02241-6. Epub 2022 Oct 14. Int J Clin Oncol. 2022. PMID: 36241930 Clinical Trial.
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, Osaki T, Kasahara N, Uchino J, Sugiyama T, Ishihara S, Ishii H, Naruse I, Mori K, Kotake M, Kanazawa K, Minato K, Kagamu H, Kaira K. Yamaguchi O, et al. Among authors: sugiyama t. Cancer Chemother Pharmacol. 2020 Apr;85(4):761-771. doi: 10.1007/s00280-020-04055-7. Epub 2020 Mar 19. Cancer Chemother Pharmacol. 2020. PMID: 32193618
Patient satisfaction with sedation for flexible bronchoscopy.
Hirose T, Okuda K, Ishida H, Sugiyama T, Kusumoto S, Nakashima M, Yamaoka T, Adachi M. Hirose T, et al. Among authors: sugiyama t. Respirology. 2008 Sep;13(5):722-7. doi: 10.1111/j.1440-1843.2008.01311.x. Epub 2008 May 29. Respirology. 2008. PMID: 18513244
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
Otani S, Sasaki J, Nakahara Y, Fukui T, Igawa S, Naoki K, Bessho A, Hosokawa S, Fukamatsu N, Nakamura Y, Kasai T, Sugiyama T, Tokito T, Seki N, Hamada A, Okamoto H, Masuda N. Otani S, et al. Among authors: sugiyama t. Invest New Drugs. 2021 Apr;39(2):530-536. doi: 10.1007/s10637-020-01031-z. Epub 2020 Nov 7. Invest New Drugs. 2021. PMID: 33159674 Clinical Trial.
Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Minemura H, Moriya H, Imai H, Sugiyama T, Yamada Y, Higuchi M, Kaira K, Ozaki Y, Kanazawa K, Yokouchi H, Kasai T, Kaburagi T, Suzuki H, Minato K, Shibata Y. Minemura H, et al. Among authors: sugiyama t. Thorac Cancer. 2020 Dec;11(12):3521-3527. doi: 10.1111/1759-7714.13695. Epub 2020 Oct 12. Thorac Cancer. 2020. PMID: 33044045 Free PMC article.
39 results